PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.

Yu TodaKenichi KohashiYuichi YamadaMasato YoshimotoShin IshiharaYoshihiro ItoTakeshi IwasakiHidetaka YamamotoYoshihiro MatsumotoYasuharu NakashimaMasaaki MawatariYoshinao Oda

Published in: Journal of cancer research and clinical oncology (2020)

Our results suggest that the PD-L1 and IDO1 immune checkpoint inhibitors may provide clinical benefit in osteosarcoma patients with metastatic lesions after conventional chemotherapy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
poor prognosis
small cell lung cancer
peritoneal dialysis
radiation therapy